BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 31775971)

  • 1. Neoadjuvant Chemoradiation Therapy Is Associated with Adverse Outcomes in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Cancer.
    Aziz H; Zeeshan M; Jie T; Maegawa FB
    Am Surg; 2019 Nov; 85(11):1276-1280. PubMed ID: 31775971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis.
    Araujo RL; Gaujoux S; Huguet F; Gonen M; D'Angelica MI; DeMatteo RP; Fong Y; Kingham TP; Jarnagin WR; Goodman KA; Allen PJ
    HPB (Oxford); 2013 Aug; 15(8):574-80. PubMed ID: 23458208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of neoadjuvant chemoradiation on pancreaticoduodenectomy—the American College of Surgeon's National Surgical Quality Improvement Program analysis.
    Teng A; Lee DY; Yang CK; Rose KM; Attiyeh F
    J Surg Res; 2015 Jun; 196(1):67-73. PubMed ID: 25791826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality.
    Denbo JW; Bruno ML; Cloyd JM; Prakash L; Lee JE; Kim M; Crane CH; Koay EJ; Krishnan S; Das P; Minsky BD; Varadhachary G; Shroff R; Wolff R; Javle M; Overman MJ; Fogelman D; Aloia TA; Vauthey JN; Fleming JB; Katz MH
    J Gastrointest Surg; 2016 Dec; 20(12):1975-1985. PubMed ID: 27730398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
    Kharofa J; Tsai S; Kelly T; Wood C; George B; Ritch P; Wiebe L; Christians K; Evans DB; Erickson B
    Radiother Oncol; 2014 Oct; 113(1):41-6. PubMed ID: 25443499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy and radiation components of neoadjuvant treatment of pancreatic head adenocarcinoma: Impact on perioperative mortality and long-term survival.
    Franko J; Hsu HW; Thirunavukarasu P; Frankova D; Goldman CD
    Eur J Surg Oncol; 2017 Feb; 43(2):351-357. PubMed ID: 27863846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
    Czosnyka NM; Borgert AJ; Smith TJ
    HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP).
    Cho SW; Tzeng CW; Johnston WC; Cassera MA; Newell PH; Hammill CW; Wolf RF; Aloia TA; Hansen PD
    HPB (Oxford); 2014 Apr; 16(4):350-6. PubMed ID: 24112766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of Prolonged Time to Pancreaticoduodenectomy After Neoadjuvant Chemoradiation.
    Teng A; Nguyen T; Bilchik AJ; O'Connor V; Lee DY
    J Surg Res; 2020 Jan; 245():51-56. PubMed ID: 31401247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients.
    Youngwirth LM; Nussbaum DP; Thomas S; Adam MA; Blazer DG; Roman SA; Sosa JA
    J Surg Oncol; 2017 Aug; 116(2):127-132. PubMed ID: 28407261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer.
    Kang CM; Choi JY; Seong JS; Song SY; Lee WJ; Kim MJ; Chung JB
    Pancreas; 2012 Apr; 41(3):467-73. PubMed ID: 22158068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer.
    Mirkin KA; Hollenbeak CS; Gusani NJ; Wong J
    Am J Surg; 2017 Jul; 214(1):80-88. PubMed ID: 27816199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study.
    Aadam AA; Evans DB; Khan A; Oh Y; Dua K
    Gastrointest Endosc; 2012 Jul; 76(1):67-75. PubMed ID: 22483859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
    Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
    Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
    Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma.
    de Geus SWL; Kasumova GG; Sachs TE; Ng SC; Kent TS; Moser AJ; Vahrmeijer AL; Callery MP; Tseng JF
    HPB (Oxford); 2018 Jun; 20(6):573-581. PubMed ID: 29426635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy.
    Cheng TY; Sheth K; White RR; Ueno T; Hung CF; Clary BM; Pappas TN; Tyler DS
    Ann Surg Oncol; 2006 Jan; 13(1):66-74. PubMed ID: 16372154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.